Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer

NPJ Breast Cancer. 2022 Mar 16;8(1):38. doi: 10.1038/s41523-022-00409-x.

Andrea Gombos^#^{1

2}, David Venet^#^{3

4}, Lieveke Ameye⁵, Peter Vuylsteke^{6

7}, Patrick Neven⁸, Vincent Richard⁹, Francois P Duhoux¹⁰, Jean-Francois Laes¹¹, Françoise Rothe^{3

4}, Christos Sotiriou^{12

3

4}, Marianne Paesmans⁵, Ahmad Awada^{12

3}, Thomas Guiot¹³, Patrick Flamen¹³, Martine Piccart-Gebhart^{12

3}, Michail Ignatiadis^#^{12

3}, Géraldine Gebhart^#¹³

¹ Medical Oncology Department, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium. [email protected].
² Université Libre de Bruxelles, Brussels, Belgium. [email protected].
³ Université Libre de Bruxelles, Brussels, Belgium.
⁴ Breast Cancer Translational Research Laboratory, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium.
⁵ Statistical Department, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.
⁶ Medical Oncology, UCLouvain, CHU Namur Site Sainte-Elisabeth, Namur, Belgium.
⁷ University of Botswana, Private Bag UB 0022, Gabarone, Botswana.
⁸ Multidisciplinary Breast Center and Department of Gynecology and Obstetrics, UZ Leuven, KU Leuven, Leuven, Belgium.
⁹ Medical Oncology CHU Ambroise Paré, Mons, Belgium.
¹⁰ Medical Oncology Cliniques Universitaires Saint-Luc, Brussels, Belgium.
¹¹ OncoDNA, Gosselies, Belgium.
¹² Medical Oncology Department, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium.
¹³ Nuclear Medicine, Institut Jules Bordet, Brussels, Belgium.

^# Contributed equally.

No abstract available

Publication types